Trial Profile
Safety and Efficacy Study of FOLFOX Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 23 Jun 2017 New trial record